Bystolic (nebivolol) / Menarini, AbbVie - LARVOL DELTA

Nebivolol Mitigates the Pro-Oxidative and Pro-Inflammatory Effects of Cyclophosphamide in the Heart. (PubMed, Fundam Clin Pharmacol) - "In conclusion, nebivolol demonstrates cardioprotective effects against the toxicity of CP by reducing pro-oxidative and pro-inflammatory responses. Thus, nebivolol may represent a novel clinical approach for managing the cardiotoxic effects associated with CP."

Journal • Cardiovascular • MT-CO2

Target the Heart: A New Axis of Alzheimer's Disease Prevention. (PubMed, J Dement Alzheimers Dis) - "Co-administering a low dose of cyclosporine A with select cardiac drugs could be a potentially effective treatment strategy for preventing Alzheimer's disease occurrence and simultaneously treating cardiovascular dysfunction, while mitigating the side effects associated with higher doses of cyclosporine A. Given that heart disease precedes Alzheimer's disease in many patients, physicians may be able to create a treatment regimen that addresses both con-ditions. Our results suggest that a calcineurin inhibitor combined with simvastatin, irbesartan, cilostazol, doxazosin, or nebivolol is the most promising candidate for future exploration."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Heart Failure

BETA-BLOCKERS ARE ASSOCIATED WITH LOWER RISK OF PANCREATIC CANCER IN PATIENTS WITH TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY (UEGW 2025) - "Primary exposure was beta-blocker use (e.g., acebutotlol, atenolol, bisoprolol, carvedilol, celiprolol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, and sotalol)...Adjusted hazard ratios (aHRs) were derived from multivariable Cox models adjusting for 31 covariates: age, sex, smoking status, alcohol use disorder, body index mass, glycemic control (in terms of time-weighted mean HbA1c), pancreatitis, cholangitis, colectomy, Charlson's comorbidity index, metabolic and cardiovascular comorbidities, and concomitant medications (aspirin, non-steroidal anti-inflammatory drugs, statins, and other antidiabetics)... Beta-blocker use was associated with a lowered risk of PC among patients with newly diagnosed T2D, in a dose- and duration-dependent manner."

Clinical • Addiction (Opioid and Alcohol) • Diabetes • Gastrointestinal Disorder • Hepatology • Metabolic Disorders • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term clinical outcomes in STEMI patients treated with drug-eluting stents (ESC-WCC 2025) - "Background: The comparative effectiveness of 2nd-generation (2G; Bisoprolol) and 3rd-generation (3G: Nebivolol, Carvedilol) β-blockers in patients with ST-segment elevation myocardial infarction (STEMI) treated with drug-eluting stents (DESs) remains unclear. In STEMI patients treated with DESs, 3G β-blockers were associated with a significantly lower incidence of MACE at 1 and 3 years compared to 2G β-blockers, while the incidence of total death was similar between the two groups. These findings suggest that 3G β-blockers may offer additional long-term benefits in this population."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range LVEF (ESC-WCC 2025) - "Background: 2nd-generation β-blockers (2G-BB, Bisoprolol), and 3rd-generation β-blockers (3G-BB, Carvedilol and Nebivolol), have different pharmacological profiles. In STEMI patients with mrEF and treated with DESs, there were no significant differences in long-term outcomes between 2nd- and 3rd-generation β-blockers in terms of total death and MACE."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%) (ESC-WCC 2025) - "In STEMI patients mrEF treated with DESs, there were no significant differences in long-term clinical outcomes between Nebivolol and Carvedilol regarding total death or MACE."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of beta-blocker nebivolol versus carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with reduced LVEF treated with drug-eluting stents (ESC-WCC 2025) - "In STEMI patients with reduced LVEF treated with DESs, discharge prescriptions of Nebivolol and Carvedilol resulted in similar long-term outcomes for all-cause death and MACE after IPTW adjustment. These findings suggest that both Nebivolol and Carvedilol are equally safe and effective options for long-term management in this population."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of nebivolol versus bisoprolol on long-term clinical outcomes in STEMI patients treated with drug-eluting stents (ESC-WCC 2025) - "In STEMI patients treated with successful DES implantation, Nebivolol and Bisoprolol demonstrated comparable long-term outcomes regarding total death and MACE at 1 and 3 years. These findings suggest that both β-blockers can be considered appropriate options for long-term management in this population."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of 2nd-generation versus 3rd-generation beta-blocker prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents (ESC-WCC 2025) - "Background: Second-generation β-blockers (2G-BB, Bisoprolol), and 3rd-generation β-blockers (3G-BB, Carvedilol and Nebivolol) have different pharmacological profiles. In STEMI patients with preserved LVEF treated with DESs, there were no significant differences in long-term clinical outcomes between 2G and 3G β-blockers. These findings suggest that both β-blocker generations offer similar clinical benefits, allowing for flexible therapeutic decisions based on individual patient needs."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of nebivolol versus carvedilol on long-term clinical outcomes in STEMI patients treated with drug-eluting stents (ESC-WCC 2025) - "In STEMI patients treated with successful DES implantation, discharge prescription of Carvedilol was associated with better long-term outcomes compared to Nebivolol, with significantly lower rates of total death and MACE at 3 years. These results suggest that Carvedilol may be a preferable β-blocker option for long-term management in this population."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents (ESC-WCC 2025) - "In STEMI patients with preserved LVEF treated with DESs, Carvedilol was associated with a significantly lower risk of all-cause death and MACE at both 1 and 3 years compared to Nebivolol. These findings suggest that Carvedilol may offer superior long-term clinical benefits in this population."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Nebivolol and Tadalafil Synergistically Ameliorate Insulin Resistance-Induced Retinopathy in Rats. (PubMed, Arch Pharm (Weinheim)) - "Interestingly, the half-dose combination of nebivolol and tadalafil significantly reduced fasting blood glucose levels and insulin resistance compared with the HFrFSD group without affecting obesity markers and lipid metabolism and showed higher protective effects against retinopathy compared with the full dose individual treatments. In conclusion, nebivolol and tadalafil synergistically ameliorate insulin resistance-induced retinopathy in rats."

Journal • Preclinical • Fibrosis • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Retinal Disorders

RaP-AF: Rate Control in Patients With Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=50 | Active, not recruiting | Sponsor: National Taiwan University Hospital | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Jun 2022 ➔ Dec 2026

Enrollment closed • Trial completion date • Atrial Fibrillation • Cardiovascular

Differential effects of β-blockers nebivolol and metoprolol on mitochondrial biogenesis and antioxidant defense in angiotensin II-induced pathology in H9c2 cardiomyoblasts. (PubMed, BMC Pharmacol Toxicol) - "In conclusion, both nebivolol and metoprolol effectively reduce oxidative stress and expression of proinflammatory genes in response to Ang II. However, nebivolol provides increased protection by restoring the antioxidant defense system and mitochondrial functions, highlighting its potential therapeutic advantage in Ang II-induced cardiac pathology."

IO biomarker • Journal • Cardiovascular • Metabolic Disorders • BCL2

Third Generation Beta-Blocker and Tacrolimus Effects on Renal Function, and Vasodilator Nitric Oxide Levels of Kidney Transplant Recipients: A Secondary Stratified Analysis (WTC 2025) - "Among KTRs, tacrolimus is associated with a trend of lower delta-NO and delta-GFR in percentile distributions of each outcome. Nebivolol has diverging associations with delta-NO and delta-GFR. The interaction between nebivolol and tacrolimus is negatively associated with more delta-NO than delta-GFR percentile distributions."

Clinical • Cardiovascular • Hypertension • Transplantation

Targeting fibrosis and steatosis: Nebivolol multi-pathway modulator ameliorates experimental non-alcoholic steatohepatitis in rats through AMPK/mTOR and TGF-β1/α-SMA pathways. (PubMed, Bioorg Chem) - "Nebivolol exerts a multi-targeted hepatoprotective effect against NASH, mainly mediated through the modulation of AMPK/mTOR and TGF-β1/α-SMA pathways, besides restoration of NO and eNOS signaling. These findings highlight Nebivolol as a promising candidate for the management of NASH and related liver disorders."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • BECN1 • IL1B • mTOR • NOS3 • PPARA • TGFB1

Urinary Bladder Paraganglioma With POT1 and RECQL4 Mutations Almost Missed by Ga-68 DOTATATE PET/CT (ENDO 2025) - "Spironolactone therapy improved blood pressure (BP) control; however, BP spikes continued along with headaches occasionally associated with voiding/bowel movements. Medications were amlodipine 10 mg/day, eplerenone 50 mg BID, nebivolol 5 mg/day, doxazosin 2 mg nightly... Bladder paragangliomas pose a diagnostic challenge. As illustrated in this case, Ga68-DOTATATE PET/CT initially missed this lesion due to the urinary excretion of the tracer highlighting the need for other imaging modalities when considering bladder PGLs. Further studies examining whether POT1 or REQL4 mutations might be pathogenic for (urinary) PGLs are warranted."

Bladder Cancer • Cardiovascular • Colonic Polyps • Endocrine Cancer • Endocrine Disorders • Follicular Lymphoma • Gastroenterology • Hematological Malignancies • Hodgkin Lymphoma • Hypertension • Lymphoma • Neuroendocrine Tumor • Oncology • Pain • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • POT1 • RECQL4 • SDHB • SYP • TP63

Development and validation of an ADRβ1-SNAP-tag/CMC model for screening ADRβ1 antagonists: Application to nebivolol and its byproducts. (PubMed, J Pharm Biomed Anal) - "In vitro calcium influx experiments verified the interaction of these components with ADRβ1, showing good inhibitory effects on ADRβ1. In conclusion, the ADRβ1 SNAP-tag/CMC model developed in this study can be used for the comprehensive screening of active components targeting ADRβ1 in complex samples."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Hirata Syndrome in a Woman With Graves' Disease Without Exposure to Thionamides and Summary of Cases from South America. (PubMed, JCEM Case Rep) - "Six months before admission, both arterial hypertension and Graves' disease were disclosed, receiving nebivolol 5 mg day only...Treatment of hypoglycemia included drug withdrawal, a fractionated diet with low-glycemic index carbohydrates, prednisone, and radioactive iodine for definitive treatment of Graves' disease, with resolution of the condition 6 months later...We did not identify any trigger factor for hypoglycemia besides Graves' disease as she did not receive any drug at hypoglycemia onset. We recommend checking for anti-insulin antibodies in cases of endogenous hyperinsulinism associated with an autoimmune disease, despite the absence of any drug treatment."

Journal • Cardiovascular • Endocrine Disorders • Grave’s Disease • Hypertension • Hypoglycemia • Immunology • Pulmonary Arterial Hypertension • Severe Hypoglycemia

Nebivolol restores the anticontractile effect of mesenteric perivascular adipose tissue lost due to obesity. (PubMed, Eur J Pharmacol) - "Overall, our results revealed that nebivolol reversed the obesity-induced loss of the anticontractile effect of the mPVAT by promoting antioxidant and anti-inflammatory effects. Hence, nebivolol represents a powerful pharmacological tool in addressing cardiovascular dysfunctions induced by obesity."

Journal • Cardiovascular • Genetic Disorders • Hypertension • Obesity • Pulmonary Arterial Hypertension • IL1B • IL6 • LEP • TNFA

The overlooked consequence of beta-blockers: impaired platelet function (ISTH 2025) - "They act on the beta-adrenergic receptors (B1, B2, and B3), thereby preventing the effects of epinephrine and norepinephrine...Beta-blockers, particularly Nebivolol, reduce the risk of thrombosis by decreasing platelet activation, a desirable effect in some instances but can increase the risk of bleeding as evidenced in this case...He did not present with anymore bleeding after the discontinuation of Nevibolol. Table or Figure Upload"

Anemia • Cardiovascular • Hematological Disorders • Hypertension • Thrombosis

Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison between Nebivolol and Telmisartan. (PubMed, Am J Hypertens) - "Nebivolol was less effective than telmisartan at reducing cSBP."

Journal • Cardiovascular • Hypertension

Calcium triggers calmodulin degradation to induce EGF receptor instability and overcome non-small cell lung cancer resistance to tyrosine kinase inhibitors. (PubMed, J Biol Chem) - "Notably, a combination of Ca2+ activator curcumin, FBXL2 activator nebivolol, and osimertinib significantly inhibits EGFRT790M/C797S-driven TKI-resistant NSCLC growth. Together, this study highlights the importance of the negative feedback loop between Ca2+ and CaM and the critical regulatory role of Ca2+/CaM in the FBXL2-mediated EGFR degradation, providing a viable therapeutic strategy for TKI-resistant NSCLC."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • FBXL2

Advanced eco-friendly spectrophotometric analysis for Nebivolol, Valsartan, and related impurity with comprehensive environmental impact assessment. (PubMed, Sci Rep) - "The proposed methods were validated as per ICH guidelines and verified to be accurate. Statistical analysis was performed to ensure the validity of methods concerning published methods."

Journal

Predictors of graft patency following coronary artery bypass graft surgery: the role of nebivolol therapy. (PubMed, Geroscience) - "Nebivolol has been found to reduce the frequency of graft occlusion following CABG, especially in case of SVG grafts. The vasodilatory properties of nebivolol may, at least in part, be responsible for the favorable effects of the drug to prevent graft occlusion."

Journal • Cardiovascular • Peripheral Arterial Disease